Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels

Journal of Clinical Psychiatry

Volumn 61, Issue 3, 2000, Pages 209-214

  Lane, Hsien Yuan ^a,b,c   Chiu, Wei Che ^b   Chou, James C Y ^a,d,e   Wu, Shaw Tein ^b   Su, Muh Hwan ^a   Chang, Wen Ho ^b,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; RISPERIDONE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STEADY STATE;

EID: 0033996265     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0311     Document Type: Article

References (36)

1. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:828-835
3. Lane HY, Liu CC, Chang WH. Risperidone for exclusively negative symptoms [letter]. Am J Psychiatry 1999;156:335
4. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997;12(4, suppl):3-10
5. Robert R, Brecher M. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Presented at the 11th annual congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
6. Collaborative Working Group on Clinical Trial Evaluations. Clinical development of atypical antipsychotics: research design and evaluation. J Clin Psychiatry 1998;59(suppl 12):10-16
7. Lane HY, Chang WH. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. J Clin Psychiatry 1999;60:487-488
8. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271-277
9. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402
10. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, baloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44
11. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
12. Pappas D, Konitsiotis S, Liakos A. Risperidone in the treatment of acute schizophrenic episodes [abstract]. Eur Neuropsychopharmacol 1997;7 (suppl 2):206
13. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:129-137
14. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25
15. Anderson C, True J, Ereshefsky L, et al. Risperidone clinical efficacy: role of the metabolite 9-hydroxy-risperidone [abstract]. Psychopharmacol Bull 1994;30:88
16. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997;17:478-484
17. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998;20:380-384
18. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998;31:102-109
19. Mauri MC, Laini V, Scalvini M, et al. Risperidone and 90H-risperidone plasma levels in schizophrenic patients. Presented at the 21st Collegium Internationale Neuro-Psychopharmacologicum; July 12-16, 1998; Glasgow, Scotland
20. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
22. Volavka J. Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? [letter] Arch Gen Psychiatry 1998;55:280-281
23. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60:469-176
24. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxy-risperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999;359:147-151
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
26. Honigfeld G, Klett CJ. The Nurses' Observation Scale for Inpatient Evaluation (NOSIE-30): a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71
27. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
28. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
29. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28:81-86
30. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-313
31. Chang WH, Lin SK, Lane HY, et al. Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 1997;96:599-605
32. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60:36-40
33. Chang WH. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology (Berl) 1992;106: 289-296
34. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423
35. Lane HY, Deng HC, Huang SM, et al. Low frequency of dextrometh-orphan O-demethylation deficiency in a Chinese population [letter]. Clin Pharmacol Ther 1996;60:696-698
36. Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995;119:345-348